BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12168874)

  • 1. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
    Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
    Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with alpha2-macroglobulin deficiency.
    Kanoh Y; Ohtani H; Egawa S; Baba S; Akahoshi T
    Clin Lab; 2012; 58(3-4):217-25. PubMed ID: 22582494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
    Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
    Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
    Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
    Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
    Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
    Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
    Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters.
    Khorramizadeh MR; Aalizadeh N; Pezeshki M; Ghahary A; Zeraati H; Berahmeh A; Safa O; Saadat F
    Int J Urol; 2005 Jul; 12(7):637-43. PubMed ID: 16045556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience.
    González Rodríguez I; Rivas del Fresno M; Gil Ugarteburu R; González Arriaga P; López Cima F; Fernández Samoano A; Muruamendiaraz Fernández V; Fernández García I; Pérez-Carral JR; Tardón A
    Arch Esp Urol; 2010 Mar; 63(2):119-24. PubMed ID: 20354276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum IgG oligosaccharide chains with prostate cancer progression.
    Kanoh Y; Mashiko T; Danbara M; Takayama Y; Ohtani S; Egawa S; Baba S; Akahoshi T
    Anticancer Res; 2004; 24(5B):3135-9. PubMed ID: 15510601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
    Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
    Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
    Bjartell A; Johansson R; Björk T; Gadaleanu V; Lundwall A; Lilja H; Kjeldsen L; Udby L
    Prostate; 2006 May; 66(6):591-603. PubMed ID: 16388501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.